MOR - MorphoSys expects 2024 Monjuvi U.S. net product sales in $80M - $95M range
2024-01-30 03:41:22 ET
More on MorphoSys
- MorphoSys: Positive Pelabresib Data Finally Unlocking Upside
- MorphoSys: A Buying Opportunity Following Mixed Phase 3 Results In Myelofibrosis
- MorphoSys: Buying Constellation Was A Desperate Measure
- MorphoSys gains amid takeover speculation
- MorphoSys climbs after late-stage data for blood cancer therapy